BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21544094)

  • 1. Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1.
    Advani SJ; Markert JM; Sood RF; Samuel S; Gillespie GY; Shao MY; Roizman B; Weichselbaum RR
    Gene Ther; 2011 Nov; 18(11):1098-102. PubMed ID: 21544094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.
    Advani SJ; Buckel L; Chen NG; Scanderbeg DJ; Geissinger U; Zhang Q; Yu YA; Aguilar RJ; Mundt AJ; Szalay AA
    Clin Cancer Res; 2012 May; 18(9):2579-90. PubMed ID: 22379115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ReVOLT: radiation-enhanced viral oncolytic therapy.
    Advani SJ; Mezhir JJ; Roizman B; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):637-46. PubMed ID: 17011442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active immunotherapy: oncolytic virus therapy using HSV-1.
    Todo T
    Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
    Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
    Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.
    Miao L; Fraefel C; Sia KC; Newman JP; Mohamed-Bashir SA; Ng WH; Lam PY
    Br J Cancer; 2014 Jan; 110(1):94-106. PubMed ID: 24196790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase.
    Stanziale SF; Petrowsky H; Joe JK; Roberts GD; Zager JS; Gusani NJ; Ben-Porat L; Gonen M; Fong Y
    Surgery; 2002 Aug; 132(2):353-9. PubMed ID: 12219034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
    Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
    Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.
    Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
    J Biomed Biotechnol; 2010; 2010():350748. PubMed ID: 20224643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation.
    Spear MA; Sun F; Eling DJ; Gilpin E; Kipps TJ; Chiocca EA; Bouvet M
    Cancer Gene Ther; 2000 Jul; 7(7):1051-9. PubMed ID: 10917208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus.
    Bradley JD; Kataoka Y; Advani S; Chung SM; Arani RB; Gillespie GY; Whitley RJ; Markert JM; Roizman B; Weichselbaum RR
    Clin Cancer Res; 1999 Jun; 5(6):1517-22. PubMed ID: 10389941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
    Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
    Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma.
    Chung SM; Advani SJ; Bradley JD; Kataoka Y; Vashistha K; Yan SY; Markert JM; Gillespie GY; Whitley RJ; Roizman B; Weichselbaum RR
    Gene Ther; 2002 Jan; 9(1):75-80. PubMed ID: 11850725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M; Rabkin SD; Martuza RL
    Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.
    Friedman GK; Langford CP; Coleman JM; Cassady KA; Parker JN; Markert JM; Yancey Gillespie G
    J Neurooncol; 2009 Nov; 95(2):199-209. PubMed ID: 19521665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic HSV-1 for the treatment of brain tumours.
    Markert JM; Parker JN; Buchsbaum DJ; Grizzle WE; Gillespie GY; Whitley RJ
    Herpes; 2006 Nov; 13(3):66-71. PubMed ID: 17147910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
    Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
    Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells.
    Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
    Bioeng Bugs; 2010; 1(6):429-33. PubMed ID: 21468212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.
    Lee TJ; Nair M; Banasavadi-Siddegowda Y; Liu J; Nallanagulagari T; Jaime-Ramirez AC; Guo JY; Quadri H; Zhang J; Bockhorst KH; Aghi MK; Carbonell WS; Kaur B; Yoo JY
    Mol Cancer Ther; 2019 Jun; 18(6):1127-1136. PubMed ID: 30926634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.